Targeted therapy using EGFR inhibitors has become the standard of care for non-small cell lung cancers that contain activating EGFR mutations [3], even though not all patients with EGFR mutations respond to EGFR inhibitors, such as erlotinib [48]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.